Samsung Seoul hospital31 May 2022 06:56
Part 1 of translation
Apicell Therapeutics (CEO Jeon Seung-ho, Yoo Jong-sang), a joint venture between Daewoong Pharmaceutical and British Avacta, signed an MOU for joint research cooperation with Samsung Seoul Hospital (President Park Seung-woo) for ‘innovative research and development in the field of cell and gene therapy’. ) was signed on the 31st.
The MOU ceremony was held at the Ilwon Station campus of Samsung Medical Center, including Jong-Sang Yoo, CEO of Apicell Therapeutics, Ki-Nam Kim, Head of Strategic Planning Office, Kyung-Hoon Ahn, Head of Strategic Planning Office, Seung-Hyeon Choi, Senior Researcher Kyu-Sung Lee, Vice President of Research and Future Medicine Research Institute at Samsung Seoul Hospital, and Yoon-Sil Jang, Cell and Gene Therapy Researcher Director, Lee Ji-hoon, director of the Gene Therapy Research Center, and Jang Jong-wook, head of the GMP cell production team, attended and exchanged agreements.
Through this MOU, the two companies plan to cooperate with each other, including ?exchanging trends and technical information in the field of gene-introduced mesenchymal stem cell therapy ? conducting joint research on national projects related to cell and gene therapy development.